Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Lifitegrast 5% Ophthalmic Solution Clear all

Conditions: Dry Eye Syndromes
Interventions: Lifitegrast 5% Ophthalmic Solution, Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Eye Surgeons of Indiana; Network
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dry Eye Disease, Dry Eye Syndrome
Interventions: AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more

Conditions: Dry Eye Disease
Interventions: Vevye®, Xiidra®; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more

Conditions: Glaucoma, Ocular Surface Disease
Interventions: Xiidra (Lifitegrast ophthalmic solution) 5%; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Dry Eye
Interventions: Lifitegrast; Drug
Lead sponsor: MDbackline, LLC; Other
Eligibility: Not listed
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Dry Eye
Interventions: Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Bucci Laser Vision Institute; Other
Eligibility: 60 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Dry Eye
Interventions: Lifitegrast 5% Ophthalmic Solution, Lifitegrast Ophthalmic Solution Vehicle; Drug · Other
Lead sponsor: State University of New York College of Optometry; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye Disease
Interventions: Lifitegrast, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 41
States / cities: Birmingham, Alabama • Chandler, Arizona • Artesia, California + 33 more

Conditions: Dry Eye
Interventions: Lifitegrast; Drug
Lead sponsor: Lifelong Vision Foundation; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions: Lifitegrast 5% Ophthalmic Solution, Placebo; Drug
Lead sponsor: Richard W Yee, MD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bellaire, Texas

Conditions: Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions: Lifitegrast; Drug
Lead sponsor: EV Clinical Trials; Other
Eligibility: 21 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Dry Eye Syndromes
Interventions: Self retained cryopreserved amniotic membrane, lifitegrast ophthalmic solution; Device · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dry Eye
Interventions: Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Research Insight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Laguna Hills, California • Jacksonville, Florida • Brecksville, Ohio

Conditions: Dry Eye Disease
Interventions: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Surface Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Azusa, California • Hemet, California + 33 more

Conditions: Dry Eye, Dry Eye Syndromes, Dry Eyes Chronic
Interventions: Lifitegrast 5% Ophthalmic Solution; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

Management of Signs and Symptoms Associated With Dry Eye Disease

The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Effect of Lifitegrast 5% on Tear Film Markers